IKS014 in Advanced Solid Tumors That Express HER2

This study is testing a new antibody-drug conjugate called IKS014 — a targeted therapy that delivers a toxic payload directly to cancer cells expressing the HER2 protein — in people with various advanced solid tumours that have HER2 expression, including low levels. **You may be eligible if...** - You have an advanced solid tumour that has HER2 expression (even at low levels — IHC 1+ or 2+) - Your cancer has progressed after standard treatments - Your blood counts and organ function are adequate (platelets ≥75,000, haemoglobin ≥9 g/dL) - Your kidney function is adequate (creatinine clearance >45 mL/min) **You may NOT be eligible if...** - Your tumour has no HER2 expression - You have received G-CSF (white blood cell booster) injections within 2 weeks of starting the study - You have significant heart problems or uncontrolled blood pressure Talk to your doctor to see if this trial is right for you.